XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 7 - Stockholder's Equity
 3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
7.             Stockholder’s Equity
 
Common Stock
 
 
In connection with the reverse merger, as discussed in Note 4, the Company ascribed non-cash consideration of $384,000 to 4,781,574 warrants outstanding prior to the reverse merger. During the three months ended March 31, 2016, the Company issued 21,242,580 shares of its common stock, of which 18,614,968 shares related to the former shareholders of RestorGenex upon the completion of the Merger, 456,427 shares were issued for advisory services provided to Diffusion LLC in connection with the merger and 2,171,185 shares were issued pursuant to conversions of convertible debt as discussed in Note 6. The Company did not purchase or retire any shares of its common stock.
 
 
Legacy RestorGenex Warrants
 
During the three months ended March 31, 2016, the Company did not grant any warrants to purchase shares of its common stock and no warrants were exercised. During the three months ended March 31, 2016, warrants to purchase an aggregate of 4,700 shares of common stock expired unexercised.
 
Warrants to purchase an aggregate of 4,776,874 shares of the Company’s common stock were outstanding and exercisable as of March 31, 2016, with per share exercise prices ranging from $2.00 to $100.00 and a weighted average exercise price of $7.99 per share.